Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928. https://doi.org/10.1016/s0140-6736(19)32591-7

Article  CAS  PubMed  Google Scholar 

McGrail DJ, Pilié PG, Rashid NU et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661–672. https://doi.org/10.1016/j.annonc.2021.02.006

Article  CAS  PubMed  Google Scholar 

Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103. https://doi.org/10.1126/science.aan4236

Article  CAS  PubMed  Google Scholar 

Vétizou M, Pitt JM, Daillère R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079–1084. https://doi.org/10.1126/science.aad1329

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalabi M, Cardona A, Nagarkar DR et al (2020) Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 31(4):525–531. https://doi.org/10.1016/j.annonc.2020.01.006

Article  CAS  PubMed  Google Scholar 

Giordan Q, Salleron J, Vallance C et al (2021) Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol 12:716317. https://doi.org/10.3389/fimmu.2021.716317

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imhann F, Bonder MJ, Vich Vila A et al (2016) Proton pump inhibitors affect the gut microbiome. Gut 65(5):740–748. https://doi.org/10.1136/gutjnl-2015-310376

Article  CAS  PubMed  Google Scholar 

Gupta A, Stokes W, Eguchi M et al (2019) Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol 90:54–66. https://doi.org/10.1016/j.oraloncology.2019.01.019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kansal V, Burnham AJ, Kinney BLC et al (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-005940

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen H, Chen S et al (2021) The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Oncoimmunology 10(1):1957605. https://doi.org/10.1080/2162402x.2021.1957605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  PubMed  Google Scholar 

McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22(8):881–886. https://doi.org/10.1007/s00384-006-0259-6

Article  PubMed  Google Scholar 

Wada A, Enokida T, Okano S et al (2023) Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 184:30–38. https://doi.org/10.1016/j.ejca.2023.02.011

Article  CAS  PubMed  Google Scholar 

Eng L, Sutradhar R, Niu Y et al (2023) Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol 41(17):3122–3134. https://doi.org/10.1200/jco.22.00074

Article  CAS  PubMed  Google Scholar 

Ritchie G, Gasper H, Man J et al (2018) Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4(4):522–528. https://doi.org/10.1001/jamaoncol.2017.5236

Article  PubMed  PubMed Central  Google Scholar 

Singh A, Alexander SG, Martin S (2023) Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy. Front Immunol 14:1114499. https://doi.org/10.3389/fimmu.2023.1114499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davar D, Zarour HM (2022) Facts and hopes for gut microbiota interventions in cancer immunotherapy. Clin Cancer Res 28(20):4370–4384. https://doi.org/10.1158/1078-0432.Ccr-21-1129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089. https://doi.org/10.1126/science.aac4255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suez J, Zmora N, Segal E et al (2019) The pros, cons, and many unknowns of probiotics. Nat Med 25(5):716–729. https://doi.org/10.1038/s41591-019-0439-x

Article  CAS  PubMed  Google Scholar 

Ferris RL, Licitra L, Fayette J et al (2019) Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res 25(17):5221–5230. https://doi.org/10.1158/1078-0432.Ccr-18-3944

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guigay J, Aupérin A, Fayette J et al (2021) Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014–01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 22(4):463–475. https://doi.org/10.1016/s1470-2045(20)30755-5

Article  CAS  PubMed  Google Scholar 

Li C, Xia Z, Li A et al (2020) The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med 8(24):1655. https://doi.org/10.21037/atm-20-7498

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riley CA, Wu EL, Hsieh MC et al (2018) Association of gastroesophageal reflux with malignancy of the upper aerodigestive tract in elderly patients. JAMA Otolaryngol Head Neck Surg 144(2):1